Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks

Launched by UNIVERSITY OF BIRMINGHAM · Mar 19, 2025

Keywords

ClinConnect Summary

The Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks study is looking to understand more about mpox, a viral infection, by gathering health information and biological samples from different groups of people. The goal is to develop better tests and vaccines to help manage mpox outbreaks in the future. Researchers are currently recruiting participants of all genders aged between 5 and 80 who are healthy and willing to take part in the study. There are three groups: one group includes people who may have been exposed to mpox, another includes those who have had mpox or have been vaccinated against it, and the third group consists of people with no symptoms or known exposure to the virus.

If you participate, you can expect to provide some health information and biological samples, like blood, that will help researchers learn more about the immune response to mpox. It's important to know that there are certain criteria that can exclude you from joining, such as having a known immune disorder, being pregnant, or having recent symptoms of mpox. This study aims to enhance our understanding of mpox so that better prevention and treatment options can be developed for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy males and females aged between ages 5-80 years, who are able and willing to provide informed consent and will comply with the study requirements.
• • Group 1 (suspected exposure cohort) only
• • Live within or adjacent to an epidemiologically identified region of Mpox transmission
• • Close contacts of those with microbiologically confirmed Mpox
• • Group 2 (post-exposure/vaccinated cohort) only
• • Previous clinically or microbiologically confirmed Mpox or confirmed previous vaccination with a smallpox/MVA vaccine
• • Fully recovered from Mpox infection
• * Group 3 (control cohort) only:
• • Asymptomatic with no known exposure to Mpox
• Exclusion Criteria:
• • Unwilling or unable to provide informed consent to take part
• • Unwilling or unable to comply with study procedures
• • History of any suspected or confirmed disorder of the immune system that, in the opinion of the investigators, might impair the results of the study
• • Have a bleeding disorder deemed significant by a member of the study team
• • Pregnant or breast-feeding females
• • Group 1 (suspected exposure cohort) only
• • Known history of Mpox infection
• • Current symptoms consistent with Mpox
• • Known exposure to Mpox in the last month
• • Group 2 (post-exposure/vaccinated cohort) only
• • Participants with any ongoing symptoms of Mpox, indicating incomplete recovery.
• • Group 3 (control cohort only)
• • Symptoms of Mpox
• • Known exposure to Mpox in the last month